Experimental combo targets tough leukemia in early trial
NCT ID NCT03844815
First seen Nov 01, 2025 · Last updated May 04, 2026 · Updated 24 times
Summary
This early-phase study tests the safety of combining the experimental drug venetoclax with a 10-day course of decitabine in adults with high-risk acute myeloid leukemia (AML). The 26 participants have AML that is relapsed, resistant, or has certain genetic markers. The main goal is to find the best dose and see how tolerable the combination is.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.